Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Return on Capital Employed (2022 - 2026)

bioAffinity Technologies has reported Return on Capital Employed over the past 5 years, most recently at 184.46% for Q1 2026.

  • Quarterly Return on Capital Employed rose 18399.0% to 184.46% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 184.46% through Mar 2026, up 18399.0% year-over-year, with the annual reading at 181.31% for FY2025, 2873.0% up from the prior year.
  • Return on Capital Employed was 184.46% for Q1 2026 at bioAffinity Technologies, down from 126.66% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 33.47% in Q4 2022 and troughed at 392.96% in Q2 2025.
  • The 5-year median for Return on Capital Employed is 151.93% (2024), against an average of 169.75%.
  • Year-over-year, Return on Capital Employed crashed -23708bps in 2025 and then soared 18399bps in 2026.
  • A 5-year view of Return on Capital Employed shows it stood at 33.47% in 2022, then plummeted by -242bps to 114.6% in 2023, then tumbled by -128bps to 261.19% in 2024, then skyrocketed by 52bps to 126.66% in 2025, then crashed by -46bps to 184.46% in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Return on Capital Employed are 184.46% (Q1 2026), 126.66% (Q4 2025), and 179.34% (Q3 2025).